NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that patient dosing is now underway in its Phase 3 registrational THRIVE-3 clinical trial evaluating intravenous (IV) Choline Chloride in patients receiving long-term parenteral support (PS). IV Choline Chloride, the Company’s investigational phospholipid substrate replacement therapy, was previously ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The ...

TARA-002 selected for FDA manufacturing development and readiness pilot programNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations for TARA-002, the Company’s investigational cell-based therapy, for the treatment of pediatric patients wit ...

Group 1 - Protara Therapeutics, Inc. has closed its underwritten public offering of 13,043,479 shares at a price of $5.75 per share, generating approximately $75 million in gross proceeds before deductions [1] - The company has granted underwriters a 30-day option to purchase an additional 1,956,521 shares at the public offering price [1] - Protara plans to use the net proceeds from the offering to fund the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1] Group 2 - J.P. Morgan, TD Cowen, and Piper Sandler served as joint book-running managers for the offering, with LifeSci Capital as the lead manager and H.C. Wainwright & Co. as a manager [2] - The shares were issued under an effective shelf registration statement on Form S-3, declared effective by the SEC on November 14, 2023 [3]

Core Viewpoint - Protara Therapeutics, Inc. has announced a public offering of 13,043,479 shares of common stock priced at $5.75 per share, aiming to raise approximately $75 million for clinical development and other corporate purposes [1]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,956,521 shares at the public offering price [1]. - The offering is expected to close on December 8, 2025, pending customary closing conditions [1]. - Protara intends to use the net proceeds for the clinical development of TARA-002 and other clinical programs, as well as for working capital and general corporate purposes [1]. Group 2: Underwriters and Management - J.P. Morgan, TD Cowen, and Piper Sandler are acting as joint book-running managers for the offering [2]. - LifeSci Capital is serving as the lead manager, while H.C. Wainwright & Co. is acting as a manager of the offering [2]. Group 3: Regulatory Information - The shares will be issued under an effective shelf registration statement on Form S-3, declared effective on November 14, 2023, by the U.S. Securities and Exchange Commission [3]. - A final prospectus supplement will be filed with the SEC and will be available on their website [3].

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants t ...

Core Insights - The article maintains optimism for Protara Therapeutics (TARA) regarding their bladder cancer pipeline, particularly in addressing drug shortages in the non-metastatic setting and exploring a novel indication [1] Company Overview - Protara Therapeutics is focused on developing treatments for bladder cancer, with a specific emphasis on addressing drug shortages [1] Analyst Background - The author has a PhD in biochemistry and extensive experience analyzing clinical trials and biotech companies, indicating a strong foundation for evaluating the company's prospects [1]

Core Insights - Protara Therapeutics (TARA) maintains optimism regarding its bladder cancer pipeline, which aims to address specific drug shortages in the non-metastatic setting and explore a novel indication [1] Company Analysis - The company is focused on developing treatments for bladder cancer, particularly in non-metastatic cases, which may present a significant market opportunity due to existing drug shortages [1] Industry Context - The analysis emphasizes the importance of understanding the science behind biotech investments, highlighting the need for thorough due diligence in this sector [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Group 1 - The call is focused on the updated interim results from the ongoing Phase II open-label ADVANCED-2 trial of TARA-002, which targets patients with non-muscle invasive bladder cancer [2] - Justine O'Malley, Senior Vice President of Investor Relations and Corporate Affairs, is leading the update call [2] - The conference is being recorded, and participants are reminded to disconnect if they have objections [1] Group 2 - Forward-looking statements will be made during the call, representing the company's views as of the current date [3] - Actual results may differ from these forward-looking statements due to various factors, as outlined in the Risk Factors section of the company's most recent annual report [4] - The company disclaims any obligation to update these forward-looking statements except as required by law [4]